Stock Research: Novartis

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Novartis

VTX:NOVN CH0012005267
24
  • Value
    50
  • Growth
    83
  • Safety
    Safety
    15
  • Combined
    33
  • Sentiment
    39
  • 360° View
    360° View
    24
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Novartis AG is a pharmaceutical company that develops and markets branded and generic prescription drugs. It operates in the pharmaceutical industry, with focus on immunology, dermatology, cancer, and more. Novartis operates globally, with a strong presence in Switzerland. In the last fiscal year, the company had a market cap of $253,332 million, profits of $38,907 million, revenue of $51,722 million, and 75883 employees.

more

ANALYSIS: With an Obermatt 360° View of 24 (better than 24% compared with alternatives), overall professional sentiment and financial characteristics for the stock Novartis are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Novartis. The consolidated Value Rank has an attractive rank of 50, which means that the share price of Novartis is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 50% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 83, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 39. Professional investors are more confident in 61% other stocks. Worryingly, the company has risky financing, with a Safety rank of 15. This means 85% of comparable companies have a safer financing structure than Novartis. ...read more

more
Index
SPI
SMI
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 7-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
50 42 53 74
Growth
83 28 25 39
Safety
Safety
15 9 22 10
Sentiment
39 74 84 68
360° View
360° View
24 17 37 36
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
11 13 34 33
Opinions Change
53 82 87 49
Pro Holdings
n/a 81 70 92
Market Pulse
39 69 61 47
Sentiment
39 74 84 68
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
50 42 53 74
Growth
83 28 25 39
Safety Safety
15 9 22 10
Combined
33 1 8 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
37 18 24 48
Price vs. Earnings (P/E)
38 60 59 75
Price vs. Book (P/B)
27 17 26 55
Dividend Yield
83 85 90 90
Value
50 42 53 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
20 14 6 26
Profit Growth
98 39 48 43
Capital Growth
81 47 31 63
Stock Returns
56 64 62 52
Growth
83 28 25 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
13 25 40 19
Refinancing
21 13 9 1
Liquidity
61 59 55 54
Safety Safety
15 9 22 10

Similar Stocks

Discover high‑ranked alternatives to Novartis and broaden your portfolio horizons.

Bachem

SWX:BANB
Country: Switzerland
Industry: Life Sciences Tools & Services
Size: Medium
Full Stock Analysis

Zehnder Group

SWX:ZEHN
Country: Switzerland
Industry: Building Products
Size: Medium
Full Stock Analysis

Ipsen

PAR:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: